{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:16:59Z","timestamp":1777904219969,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"NRC-IRAP"},{"name":"European Union's program Eurostar"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diabetic retinopathy is a major cause of vision loss in adults. Novel eye\u2010drop formulations of candesartan and irbesartan are being developed for its cure or treatment. To support a preclinical trial in rabbits, it was critical to develop and validate a new LC\u2013MS\/MS method for simultaneous quantification of candesartan and irbesartan in rabbit eye tissues (cornea, aqueous humor, vitreous body and retina\/choroid). Eye tissue samples were first homogenized in H<jats:sub>2<\/jats:sub>O\u2010diluted rabbit plasma. The candesartan and irbesartan in the supernatants together with their respective internal standards (candesartan\u2010d<jats:sub>4<\/jats:sub> and irbesartan\u2010d<jats:sub>4<\/jats:sub>) were extracted by solid\u2010phase extraction. The extracted samples were injected onto a C<jats:sub>18<\/jats:sub> column for gradient separation. The MS detection was in the positive electrospray ionization mode using the multiple reaction monitoring transitions of <jats:italic>m\/z<\/jats:italic> 441\u2009\u2192\u2009263, 445\u2009\u2192\u2009267, 429\u2009\u2192\u2009207, and 433\u2009\u2192\u2009211 for candesartan, candesartan\u2010d<jats:sub>4<\/jats:sub>, irbesartan and irbesartan\u2010d<jats:sub>4<\/jats:sub>, respectively. For the validated concentration ranges (2\u20132000\u2009and 5\u20135000\u2009ng\/g for candesartan and irbesartan, respectively), the within\u2010run and between\u2010run accuracies (% bias) were within the range of \u22128.0\u201310.0. The percentage CV ranged from 0.6 to 7.3. There was no significant matrix interference nor matrix effect from different eye tissues and different rabbits. The validated method was successfully used in the Good Laboratory Practice (GLP) study of rabbits.<\/jats:p>","DOI":"10.1002\/bmc.4808","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T23:02:04Z","timestamp":1582671724000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Simultaneous quantification of candesartan and irbesartan in rabbit eye tissues by liquid chromatography\u2013tandem mass spectrometry"],"prefix":"10.1002","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5313-8650","authenticated-orcid":false,"given":"Aimin","family":"Tan","sequence":"first","affiliation":[{"name":"Nucro\u2010Technics  Scarborough ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Gui","sequence":"additional","affiliation":[{"name":"Nucro\u2010Technics  Scarborough ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Wong","sequence":"additional","affiliation":[{"name":"Nucro\u2010Technics  Scarborough ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Deng","sequence":"additional","affiliation":[{"name":"Nucro\u2010Technics  Scarborough ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guifen","family":"Gu","sequence":"additional","affiliation":[{"name":"Nucro\u2010Technics  Scarborough ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantine","family":"Fanaras","sequence":"additional","affiliation":[{"name":"Nucro\u2010Technics  Scarborough ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Fanaras","sequence":"additional","affiliation":[{"name":"Nucro\u2010Technics  Scarborough ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"10200","article-title":"A study of the possible effect of pomegranate juice on the pharmacokinetics of candesartan in rat plasma by using a bioanalytical method\u2014liquid chromatography\/mass spectrometry (HPLC\/MS\/MS)","volume":"8","author":"Al\u2010Kawaz A.","year":"2016","journal-title":"International Journal of PharmTech"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00251922"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2006.10.002"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.12.83"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.05.069"},{"key":"e_1_2_6_7_1","unstructured":"European Medicines Agency(2011).Guideline on Bioanalytical Method Validation.https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.17344\/acsi.2015.1836"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2019-0149"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.4103\/0975-7406.116792"},{"key":"e_1_2_6_11_1","first-page":"335","article-title":"LC\u2010MS\/MS assay for irbesartan in human plasma using solid phase extraction technique: A pharmacokinetic study","volume":"7","author":"Katteboina M. Y.","year":"2015","journal-title":"International Journal of Pharmacy and Pharmaceutical Sciences"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5850"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-015-0026-2"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118671276"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826076.2011.615092"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2010.01992.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.10.60"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.6239"},{"key":"e_1_2_6_19_1","first-page":"96","article-title":"Determination of irbesartan and sinensetin simultaneously by liquid chromatography tandem mass spectrometry and their application to drug interaction study in rat plasma","volume":"8","author":"Nurmeilis, Harahap Y.","year":"2016","journal-title":"International Journal of Pharmacy and Pharmaceutical Sciences"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229-4708.84460"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2011.05.024"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02552.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.14.198"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119413073.ch9"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4409"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2017.11.008"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.08.019"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2016.06.010"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2009.10.023"},{"key":"e_1_2_6_30_1","unstructured":"US Food and Drug Administration(2018).Guidance for industry: Bioanalytical method validation.https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf."},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.07.024"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70256-6"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbmc.4808","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.4808","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bmc.4808","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.4808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:03:45Z","timestamp":1760058225000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.4808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1002\/bmc.4808"],"URL":"https:\/\/doi.org\/10.1002\/bmc.4808","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,25]]},"assertion":[{"value":"2019-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e4808"}}